Analysis of the impact of platinum-based combination chemotherapy in small cell cervical carcinoma: a multicenter retrospective study in Chinese patients

Huang, Long; Liao, Ling-Min; Liu, An-Wen; Wu, Jian-Bing; Cheng, Xiao-Ling; Lin, Jia-Xin; Zheng, Min

doi:10.1186/1471-2407-14-140

Table 2 Treatment plans and outcomes of the 72 cases of small cell cervical carcinoma

From: Analysis of the impact of platinum-based combination chemotherapy in small cell cervical carcinoma: a multicenter retrospective study in Chinese patients

Case	Age	FIGO stage	Treatment			Response to CT	Outcome (months)
			Surgery	PMCT	PMRT
1	29	Ia	Yes	EP ×4	No	CR	NED (98 M)
2	52	IIa	Yes	/	Yes	/	DOD (8 M)
3	27	Ib2	Yes	TP ×4	Yes	CR	NED (42 M)
4	58	Ib1	Yes	VAC ×4	Yes	PR	NED (23 M)
5	42	Ib2	Yes	VAC ×1 + EP ×6	No	PROG	DOD (17 M)
6	39	Ib2	Yes	CBP ×2 + TP ×4	No	SD	DOD (28 M)
7	54	IIIb	Yes	P ×1	No	PROG	DOD (25 M)
8	43	Ib1	Yes	/	No	/	NED (119 M)
9	36	Ib1	Yes	CAP ×2	No	PROG	DOD (22 M)
10	47	Ib1	Yes	CBP ×4	Yes	CR	NED (70 M)
11	46	Ib2	Yes	ITP ×4	Yes	SD	DOD (34 M)
12	38	IIa	Yes	CBP ×4	Yes	SD	DOD (38 M)
13	58	IIa	Yes	/	No	/	DOD (6 M)
14	48	IIb	Yes	/	Yes	/	DOD (2 M)
15	24	Ib2	Yes	IP ×1	Yes	PROG	DOD (5 M)
16	51	Ib1	Yes	VAC ×2 + EP ×2	No	PROG	DOD (23 M)
17	65	IIa	Yes	VAC ×2 + EP ×1	Yes	PROG	DOD (23 M)
18	37	IIb	No	/	Yes	/	DOD (6 M)
19	42	IIa	Yes	VAC ×2 + EP ×2	Yes	PR	DOD (33 M)
20	51	Ib2	Yes	EP ×4	No	CR	NED (43 M)
21	36	Ib1	Yes	TP ×4	Yes	PR	DOD (11 M)
22	48	Ib2	Yes	VAC ×2 + EP ×2	No	PR	NED (32 M)
23	55	Ib1	Yes	(IP + CP) ×5	No	PROG	DOD (28 M)
24	41	Ib1	Yes	EP ×3	No	PR	NED (20 M)
25	32	IIb	No	/	Yes	/	NED (63 M)
26	40	IIIb	Yes	TP ×5	Yes	PR	NED (64 M)
27	44	Ib1	Yes	EP ×4	/	CR	NED (59 M)
28	34	Ib1	No	VAC ×2 + EP ×2	No	PR	NED (22 M)
29	62	IIb	Yes	/	/	/	NED (20 M)
30	41	Ib2	Yes	EP ×4	Yes	CR	NED (17 M)
31	56	Ib1	Yes	EP ×4	Yes	CR	NED (46 M)
32	66	IIa	Yes	EP ×4	No	CR	NED (12 M)
33	39	IIb	No	/	Yes	/	DOD (12 M)
34	38	Ib1	Yes	EP ×4	Yes	SD	DOD (18 M)
35	54	Ib1	Yes	EP ×4	No	PR	NED (15 M)
36	39	Ib1	Yes	EP ×4	Yes	PR	NED (13 M)
37	38	Ib1	Yes	EP ×4	No	CR	NED (24 M)
38	51	IIa	Yes	EP ×4	No	CR	NED (25 M)
39	47	Ib1	Yes	EP ×4	Yes	PR	NED (26 M)
40	28	IV	No	/	/	/	DOD (1 M)
41	40	Ib2	No	/	/	/	NED (8 M)
42	48	Ib1	Yes	EP ×4	No	CR	NED (21 M)
43	57	IIa	Yes	EP ×4	Yes	CR	NED (11 M)
44	29	Ib2	Yes	/	No	CR	NED (29 M)
45	38	IIa	Yes	EP ×4	Yes	SD	DOD (18 M)
46	59	Ib1	Yes	EP ×4	No	/	NED (16 M)
47	61	Ib1	Yes	EP ×4	No	CR	NED (24 M)
48	43	Ib2	Yes	EP ×4	Yes	CR	NED (28 M)
49	40	Ib1	Yes	EP ×4	No	CR	NED (13 M)
50	42	Ib1	Yes	VAC ×4	No	CR	NED (74 M)
51	45	Ib1	Yes	/	No	/	DOD (19 M)
52	52	Ib2	Yes	EP ×4	No	CR	NED (46 M)
53	26	Ib1	Yes	EP ×4	/	CR	NED (32 M)
54	31	IIb	No	EP ×4 + VAC ×2	Yes	PR	DOD (17 M)
55	55	Ib1	Yes	EP ×4	No	CR	NED (50 M)
56	50	Ib1	Yes	EP ×5	Yes	PR	DOD (29 M)
57	44	Ib2	Yes	EP ×4	No	CR	DOD (33 M)
58	54	Ib1	Yes	/	Yes	/	DOD (38 M)
59	43	IIa	Yes	/	Yes	/	DOD (15 M)
60	40	Ib2	Yes	TP ×4	No	PR	DOD (34 M)
61	36	IIa	Yes	/	Yes	/	DOD (14 M)
62	46	Ib1	Yes	EP ×4	No	PR	DOD (49 M)
63	48	IIb	Yes	EP ×4	Yes	PR	DOD (20 M)
64	31	Ib1	Yes	EP ×4	/	CR	NED (10 M)
65	33	IIb	No	VAC ×2 + EP ×6	Yes	PROG	DOD (11 M)
66	67	IIa	Yes	EP ×4	Yes	CR	NED (18 M)
67	53	IIb	No	/	Yes	/	DOD (6 M)
68	38	IIa	Yes	EP ×4 + VAC ×2	Yes	PR	DOD (34 M)
69	42	Ia	Yes	EP ×4	No	PR	NED (32 M)
70	66	IIb	Yes	/	No	/	DOD (5 M)
71	45	Ib2	Yes	EP ×4	Yes	CR	NED (15 M)
72	41	Ib1	Yes	EP ×4	Yes	CR	NED (13 M)

PMCT, postoperative chemotherapy; PMRT, postoperative radiotherapy; CT, chemotherapy; EP, etoposide + cisplatin; VAC, vincristine + doxorubicin + cyclophosphamide; TP, paclitaxel + cisplatin; CBP, cyclophosphamide + bleomycin + carboplatin/cisplatin; CBP, cyclophosphamide + adriamycin + carboplatin/cisplatin; ITP, ifosfamide + pirarubicin + cisplatin; CR, complete response; PR, partial response; SD, stable disease; PROG, progressive disease; M, months; DOD, died of disease; NED, no evidence of disease.

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us